EP03.01-011 Prevalence of KRASMutations in Treatment-naïve Non-small Cell Lung Cancer Patients in Hong Kong

Abstract

There are limited studies on the prevalence of KRAS and KRAS G12C mutations in Chinese NSCLC patients in mainland China, reporting from a range of 7.5% to 9.8% KRAS mutations and 2.1% to 4.3% KRAS G12C mutation in NSCLC patients. In addition to genetic factors, the difference in environmental and lifestyle factors may potentially affect the prevalence of KRAS and KRAS G12C mutations therefore the aim of this study is to examine the prevalence in Hong Kong NSCLC patients.